Androgen Deprivation Therapy News and Research

RSS

Moffitt researchers reveal a mechanism leading to drug resistance in prostate cancer

Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy.

16 Jun 2022

Androgens contribute to sex bias in bladder cancer

Male sex hormones interfere with the body's ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study co-led by a Cedars-Sinai Cancer investigator.

10 Jun 2022

New androgen biosynthesis inhibitor drug for prostate cancer shows mixed results

A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies, according to a study published in the Journal of Clinical Oncology.

31 May 2022

Combined treatment approach proves to be beneficial for prostate cancer patients

Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy-;a commonly used hormone injection-;plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients' prostate cancer at bay for five years.

26 May 2022

The link between androgens and COVID-19

A new paper examines the association between androgens and COVID-19, as revealed by the research carried out on this topic throughout the pandemic.

20 May 2022

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

A recent study published in the journal Immunology analyzed whether sex mattered in the immune response to SARS-CoV-2.

29 Apr 2022

Study reveals the oncometabolite role of progesterone in advanced prostate cancer

In a study published in Cell Reports Medicine, a group of Chinese scientists revealed the oncometabolite role of progesterone in advanced prostate cancer and strategies to eliminate its oncogenic effect as an aspect of prostate cancer treatment.

15 Mar 2022

Novel radioligand therapy shown to increase survival of metastatic prostate cancer patients

A novel prostate cancer treatment-;225Ac-PSMA-617 radioligand therapy-;has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear Medicine.

9 Mar 2022

Choice of initial treatment not related to depression, emotional well-being in prostate cancer patients

Depression and other mental health outcomes are similar for men choosing different options for initial treatment of localized prostate cancer, reports a study in The Journal of Urology, an Official Journal of the American Urological Association.

3 Mar 2022

Study finds the optimal duration of treatments for patients with high-risk prostate cancer

Patients receiving radiotherapy to treat high-risk prostate cancer also benefit from androgen deprivation therapy.

25 Feb 2022

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

A new drug, administered in combination with standard androgen-deprivation therapy and docetaxel chemotherapy, increased survival in patients with metastatic hormone-sensitive prostate cancer, according to a trial published in The New England Journal of Medicine.

23 Feb 2022

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases.

18 Feb 2022

Study findings could help guide treatment planning for men with high-risk prostate cancer

Results of a large study led by UCLA Jonsson Comprehensive Cancer Center researchers could help guide treatment planning for patients with high-risk prostate cancer.

20 Jan 2022

Addition of hormone therapy to radiotherapy treatments improves survival in prostate cancer patients

Prostate cancer is the leading cause of cancer in men worldwide, and radiotherapy is one of the common forms of treatment.

18 Jan 2022

Black men with prostate cancer may have improved response to radiation therapy than white men

UCLA Jonsson Comprehensive Cancer Center researchers leading a meta-analysis of seven randomized trials found an "unexpected result": Although Black men appeared to have more aggressive disease when they enrolled in clinical trials of radiation therapy for prostate cancer, their treatment outcomes and disease-specific outcomes were better than those of their white counterparts.

30 Dec 2021

Study provides new insights into molecular drivers of treatment resistance in prostate cancer

An international research team co-led by scientists at Roswell Park Comprehensive Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified an important accelerator of treatment-resistant prostate cancer.

14 Dec 2021

Impact of tumor environments on susceptibility and course of disease in those infected with SARS-CoV-2

A review assessed the impact of "hot" vs. "cold" immune/tumor environments (and associated therapies) on susceptibility and disease course in subjects with these two types of tumors and infected with SARS-CoV-2 to decipher the mechanisms that drive these adverse outcomes in COVID-19 infected cancer patients.

13 Dec 2021

Compound extracted from orchid could be a potential treatment option for prostate cancer

Research led by the Centenary Institute has found that a compound extracted from a commonly cultivated orchid could be a potential new treatment option for prostate cancer.

22 Sep 2021

Cardiovascular safety of prostate cancer treatments remains unresolved

The relative cardiovascular safety of different types of androgen deprivation therapy (ADT) for prostate cancer remains unresolved after the PRONOUNCE trial was terminated early. The late breaking research is presented in a Hot Line session today at ESC Congress 2021.

30 Aug 2021

Does SARS-CoV-2 affect male fertility?

A recently published review describes the state of current knowledge regarding the impact of SARS-CoV-2 on the male reproductive system.

23 Aug 2021